Answers are grounded in this paper and cite their sources.
Demonstrates sustained blood sugar control in diabetic models using long-acting circRNA therapies, suggesting new treatment potential.
• Designed a scarless and flexible circRNA production platform with low immunogenicity based on Td PIE method. • Optimized circRNA translational efficiency in IRES and regulatory elements. • Synthesized circRNA expressing long-acting GLP-1RA for therapeutic application in a type 2 diabetes model, with single-dose efficacy lasting 7 days. • Feasibility of large-scale circRNA production in bacteria. Glucagon-like peptide-1 (GLP-1) is a prominent therapeutic agent capable of normalizing fasting blood glucose levels in diabetic patients. While GLP-1-expressing mRNA encapsulated in lipid nanoparticles (LNPs) has been evaluated for diabetes treatment in primate models, circular RNAs (circRNAs) represent a more stable alternative to linear mRNA, offering significant potential for the development of next-generation GLP-1-encoding RNA therapeutics. This study aims to design and synthesize a safe, long-acting circRNA encoding a GLP-1 receptor agonist (GLP-1RA). We developed a scarless PIE (SLPIE) system that embeds essential exonic sequences within a split internal ribosome entry site (IRES), thereby minimizing immunogenicity. Scarless circRNAs expressing GLP-1RA or its analogs were synthesized using this SLPIE platform, encapsulated in LNPs, and evaluated for antidiabetic efficacy. Our SLPIE system facilitated efficient RNA circularization. Systematic optimization identified the EV-B107_IRES as highly compatible with the SLPIE strategy and superior in translational efficiency. Incorporating 5–7% m⁶A modification during RNA synthesis enhanced translation via DOPE-based LNPs while maintaining minimal immunogenicity. Notably, scarless circRNAs encoding GLP-1 or its derivative, GLP-1_FcBO (fused with an IgG-Fc affinity peptide), demonstrated potent and sustained hypoglycemic and anti-obesity effects in diabetic mice, matching the efficacy of Semaglutide over a 7-day period. Additionally, we established a scalable production platform using an RNase III -deficient E. coli strain. The SLPIE system thus offers a simple, flexible, and scalable advancement for circRNA therapeutics and opening new avenues for treating diabetes and obesity.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: